Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Background: HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resistance or the emergence of acquired resistance is a persistent clinical problem. Here we report that neratinib, an irreversible pan-HER inhibitor, in combination with the multi-...

Full description

Bibliographic Details
Main Authors: Neil T Conlon, Sandra Roche, Amira F Mahdi, Alacoque Browne, Laura Breen, Johanna Gaubatz, Justine Meiller, Fiona O'Neill, Lorraine O'Driscoll, Mattia Cremona, Bryan T Hennessy, Lisa D Eli, John Crown, Denis M Collins
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:Translational Oncology
Subjects:
Breast cancer
HER2-positive
Targeted therapies
Tyrosine kinase inhibitors
Neratinib
Dasatinib
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523324002006

Internet

http://www.sciencedirect.com/science/article/pii/S1936523324002006

Similar Items